Clinical management of community-acquired pneumonia;Manejo clínico de las neumonías adquiridas en la comunidad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 7, 2003, Pages 350-357

  Pachón, Jerónimo ^a   De Dios Alcántara, Juan ^b   Cordero, Elisa ^b   Lama, Carmen ^b   Rivero, Antonio ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN;

ANTIBIOTIC SENSITIVITY; ASPIRATION PNEUMONIA; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PNEUMONIA; REVIEW; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE;

EID: 0141569844     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050526     Document Type: Review

References (66)

1. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine JM. Practice guidelines for the management fo community-acquired pneumonia in adults. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, and the Canadian community-acquired pneumonia working group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163: 1730-54.
4. Gross PA, Barrett TL, Dellinger P, Krause PJ, Martone WJ, McGowan Jr JE, et al. Purpose of quality standars for Infectious Diseases. Clin Infect Dis 1994;18:421.
5. Pachón J, Cordero E, Caballero FJ. Importancia de otros patógenos piógenos clásicos (Staphylococcus aureus, bacilos gramnegativos y otros) en la neumonía adquirida en la comunidad. Med Clin (Barc) 1998;110(Supl 1):65-70.
6. Pachón J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonía. Am Rev Respir Dis 1990;142:369-73.
7. Zalacain R, Sobradillo V. Pacientes con neumonía comunitaria que no requieren hospitalización. Med Clin (Barc) 2001;(Supl 2):12-5.
8. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguijar L, García de Lomas J, et al, and the Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother 2001;45:3334-40.
9. Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333: 474-80.
10. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(Suppl 3):38-44.
11. Davies TA, Kelly LM, Jacobs MR, Appelbaum PC. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test and disk difussion methodologies. J Clin Microbiol 2000;38:1444-8.
12. Reinert RR, Bryskier A, Lütticken R. In vitro activities of new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother 1998;42:1509-11.
13. Verhaegen J, Verbist L. Comparative in vitro activity of telithromycin and other antibiotics against 637 S. pneumoniae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, September 17-20, 2000. [Abstract n.o 2156].
14. Perea EJ. Levofloxacino, actividad in vitro. Enferm Infecc Microbiol Clin 1999;17(Suppl 1):8-13.
15. Dalhoff A, Krasemann C, Wegener S, Tilotson G. Penicillin-resistant Sstreptococcus pneumoniae: review of moxifloxacin activity. Clin Infect Dis 2001;32(Suppl 1):S22-9.
16. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, De Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
17. Jones RN, Pfaller MA. Macrolide and fluorquinolone (levofloxacin) resistance among Streptococcus pneumoniae strains. Significant trends from the SENTRY antimicrobial surveillance program (North America 1997-1999). J Antimicrob Chemother 2000;38:4298-9.
18. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117(Suppl 2):380-5.
19. Doern GV, and the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-1993 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996;38(Suppl A):59-69.
20. Berck SL, Kalbfleisch JH, and the Alexander Project Collaborative Group. Antibiotic susceptibility patterns of community-acquired respiratory isolates of Moraxella catarrhalis in Western Europe and in the USA. J Antimicrob Chemother 1996;38(Suppl A):85-96.
21. Álvarez F, Bouza E, García-Rodríguez JA, Mayer MA, Mensa J, Monso E, et al. Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica. Rev Esp Quimioterap 2001;14:87-96.
22. Ramírez de Arellano E, Perea EJ. Actividad comparada de diversos macrólidos sobre cepas de Haemophilus influenzae. Rev Esp Quimioterap 2000;13:291-6.
23. Boswell FJ, Wise R. Advances in the macrolides and quinolones. Infect Dis Clin North Am 1998;12:647-68.
24. Sáez-Nieto JA, Vázquez JA. In vitro activities of ketolides HRM 3647 and HRM 3004, levofloxacin and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis. Antimicrob Agents Chemother 1999;43:983-4.
25. Dubois J, St-Pierre C. In vitro study of the minimal inhibitory concentrations (MIC) of Telithromycin (HMR 3647), macrolides and quinolones against Haemophilus, Streptococcus and Moraxella strains obtained from upper and lower respiratory tract infections and from maxillary sinus aspiration. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20 2000 [Abstract n.o 2152].
26. Wootton M, Bowker KE, Janowska A, Holt HA, Macgowan AP. In vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci. J Antimicrob Chemother 1999;44:445-53.
27. Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998;31:349-53.
28. Bauerfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, Clinafloxacin, Levofloxacin abd ciprofloxacin. J Antimicrob Chemother 1997;40:639-51.
29. Fass RJ. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997;41:1818-24.
30. Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 2001;7(Suppl 3):2-10.
31. Schulin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998;42:1520-3.
32. Dalhoff A. In vitro activities of quinolones. Exp Opin Invest Drugs 1999;8: 123-37.
33. Kleinkauf N, Ackermann G, Schaumann R, Rodloff AC. Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 2001;45:1896-9.
34. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
35. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
36. British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86: 7-13.
37. Bates JH, Campbell GD, Barron AL, McCracken GA, Morgan PN, Moses EB, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992;101:1005-12.
38. Arbo MDJ, Snydman DR. Influence of blood culture results on antibiotic choice in treatment of bacteriemia. Arch Intern Med 1994;154:2641.
39. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978;74:170-3.
40. Oteo J, Alos JL, Gómez-Garcés JL. Sensibilidad in vitro actual de los patógenos respiratorios bacterianos más frecuentes: Implicaciones clínicas. Med Clin (Barc) 2001;116:541-9.
41. Bertrán MJ, Trilla A, Codina C, Carné X, Ribas M, Asenjo MA. Análisis de la relación coste-efectividad del tratamiento antibiótico empírico en pacientes con infecciones del tracto respiratorio inferior adquiridas en la comunidad. Enfer Infecc Microbiol Clin 2000;18:445-51.
42. Torres A, Soler N. Revisión de las diferentes normativas sobre el tratamiento de la neumonía adquirida en la comunidad. Med Clin (Barc) 2001;Monogr 2:80-6.
43. Ben-David D, Rubinstein E. Appopriate use of antibiotics for respitarory infections. Review of recent statement and position papers. Curr Op Infect Dis 2002;15:151-6.
44. Dorca Sargatal J, Bello Dronda S, Blanquer Olivas JM, Celis Valeri MR, Molinos Martí L, Verano Rodríguez A, et al. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Recomendaciones SEPAR. 1997.
45. Read RC. Evidence-based medicine: Empiric antibiotic therapy in community-acquired pneumonia. J Infect 1999;39:171-8.
46. File TM. Judicious use of antibiotics to treat respiratory tract infections. Curr Op Infect Dis 2002;15:149-50.
47. Torres A, Soler N. Evaluación de la etiología y del abordaje terapéutico de la neumonía adquirida en la comunidad. Med Clin (Barc) 2001;116:179-81.
48. European Study on Community-Acquired Pneumonia (ESOCAP) Committee. Protocolos diagnósticos terapéuticos para las infecciones extrahospitalarias del tracto respiratorio inferior en el adulto. Eur Respir J 1998;11:986-91.
49. Metersky ML. Community-acquired pneumonia: Process of care studies. Curr Op Infect Dis 2002;15:69-174.
50. Pachón J, Cordero E, Rodríguez MJ. Neumonía de la comunidad. En: Programa de Aproximación al Diagnóstico: Enfermedades Infecciosas en Atención Primaria. Unidad 3. Año 2.000. Patrocinado por la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, Edit. Drug Farma. Madrid; 37-52.
51. Meehan TP, Fine MJ, Kruhlz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcome in elderly with pneumonia. JAMA 1997;278:2080-4.
52. Battleman DS, Callahan M, Thaller HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce lenght of hospital stay in patients with community-acquired pneumonia. Arch Intern Med 2002;162:682-8.
53. Rosón B, Carratalá J, Tubau F, Dorca J, Linares J, Pallarés R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001;7:75-85.
54. Ramírez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-54.
55. th European Congress of Clinical Microbiology and Infectious Diseases. Estambul, Turquía, April 1-4, 2001. [Abstract P862].
56. Chien SC, Rogge MC, Gliscon LG, Curtin C, Wong F, Natarajan J, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-miligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.
57. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, et al. Pharmacokinetics of once-daily oral dose of moxifloxacin (Bay 12-8039) a new enantomerically pure 8-methoxi quinolone. Antimicrob Agents Chemother 1999;43:2793-7.
58. Kalbematter V, Bagilet D, Diab M, Jaikin E. Levofloxacino oral frente a ceftriaxona y a amoxicilina-ácido clavulánico intravenoso en el tratamiento de la neumonía de adquisición comunitaria que requiere hospitalización. Med Clin (Barc) 2000;115:561-3.
59. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simón S, Armengou-Arxe A, Bisbe-Company V, Peñarroja-Matutano G, et al. Efficacy and safety of oral and early swith to therapy for community-acquired pneumonia: A randomized controlled trial. Am J Med 2001;111:367-74.
60. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-72.
61. Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia: Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:3128.
62. Germaud P, Poirier J, Jacqueme P, Guerin JC, Benard Y, Boutin C, et al. Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess: A propos of 57 cases. Rev Pneumol Clin 1993;49:137-41.
63. Pachón J, Falguera M, Gudiol F, Sabriá M, Álvarez-Lerma F, Cordero E. Infecciones del tracto respiratorio inferior. Protocolos clínicos SEIMC. 2000.
64. Marrie T, Lau C, Wheeler S, Wong C, Vandervoort M, Feagan B. A controlled trial of a clinical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial. JAMA 2000; 283:749-55.
65. Rhew DC, Weingarten SR. Achieving a safe and early discharge for patients with community-acquired pneumonia. Med Clin North Am 2001;85:1427-40.
66. Donowitz GR, Mandell GL. Acute pneumonia. En: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone, 2000; p. 717-43.